AZD2962

DRUG3 trials

Sponsors

AstraZeneca AB, Hibi Kazushige, AstraZeneca

Conditions

Dysplastic chronic myelomonocytic leukaemiaHaematologic NeoplasmsMyelodysplastic syndromes

Phase 1

A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)

RecruitingNCT07064122

AstraZenecaHaematologic Neoplasms

Start: 2025-11-03End: 2028-10-20Target: 72Updated: 2026-03-02

A Modular Phase I/II, Open-label, Multicentre Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of AZD2962, an IRAK4 inhibitor, as Monotherapy and in Combination with other Agents, in Participants with Hematologic Neoplasms

RecruitingCTIS2025-520786-44-00

AstraZeneca ABDysplastic chronic myelomonocytic leukaemia, Myelodysplastic syndromes

Start: 2025-10-21Target: 7Updated: 2025-12-10

Phase 2

A study of AZD2962, an IRAK4 inhibitor, in Participants with Haematologic Neoplasms

RecruitingJPRN-jRCT2031250235

Hibi KazushigeHaematologic Neoplasms

Start: 2025-07-07Target: 72Updated: 2025-08-15